The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face competition from cheaper generics.

Farley singled out imports from Japan and South Korea that have little to no duties compared to the 25% tariff threatened on Canada and Mexico.